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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
￿ Statins reduce cholesterol concentrations
and cardiovascular events in randomized
clinical trials.
￿ Much less is known about their impact in
the setting of normal care.
WHAT THIS STUDY ADDS
￿ This is the ﬁrst study to assess the
effectiveness of lipid-lowering treatment in
the general population.
￿ We have also estimated the resultant impact
on major vascular events.
￿ We have examined the actual and potential
impact of lipid-lowering treatment.
AIMS
To evaluate the impact of lipid-lowering treatment on cholesterol
concentrations in the setting of normal care.
METHODS
This was a retrospective review of all cholesterol measurements made in
Tayside,Scotland,between 1993 and 2002,linked to dispensed prescrib-
ing data for lipid-lowering drugs.It was conducted in the setting of
normal care and included all patients who underwent cholesterol mea-
surement.The main outcome measure was cholesterol concentration.
RESULTS
A total of 401 489 cholesterol measurements were made on 128 240
patients over the study period.Measurements were categorized as
treated and untreated according to whether patients were exposed to
lipid-lowering treatment at the time the total cholesterol concentration
was measured.Those categorized as untreated fell by 0.86 mmol l-1
(13.9%) and those categorized as treated by 1.45 mmol l-1 (23.5%).The
difference between baseline and follow-up cholesterol concentrations
in intention-to-treat patients was 1.53 mmol l-1 (24%) in 2002.In the
same year,mean cholesterol concentration was 4.71 mmol l-1 (a fall of
1.65 mmol l-1 or 25.9%) in patients judged to be taking their
lipid-lowering medication,compared with 5.20 mmol l-1 (a fall of
1.16 mmol l-1 or 18.2%) in those judged not to be taking treatment.
Cholesterol fell by 0.38 mmol l-1 (6.3%) in a cohort of never treated
patients (n = 33 679) between 1993 and 2002.
CONCLUSIONS
The impact of lipid-lowering drugs on population cholesterol
concentrations in the setting of normal care was signiﬁcant and
comparable with the cholesterol reductions seen in the setting of
major statin trials,despite a signiﬁcant proportion of the population
receiving low dose treatment.In those subjects judged to be taking
their medication,the beneﬁts achieved were substantial.The impact of
nondrug factors is indicated by the fall in population cholesterol seen
in the absence of lipid-lowering treatment.
Re-use of this article is permitted in accordance with the Creative Commons Deed,Attribution 2.5,which does not permit commercial exploitation.
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Statin trials have ended the debate about whether lipid-
lowering treatment can reduce cardiovascular events [1].
Much less is known about the effectiveness of lipid-
loweringtreatmentinthesettingofnormalcare.Although
serial health surveys have documented rising use of lipid-
loweringdrugsandmoreaggressivelipidmanagement[2,
3], population-based studies are required to establish the
true impact of lipid-lowering drugs on cholesterol concen-
trations. We applied population-based, record-linkage
methodology in order to assess the impact of lipid-
lowering drugs on cholesterol concentrations in Tayside,
Scotland,between 1993 and 2002.
Methods
Our study was conducted using data from the Tayside
Medicines Monitoring Unit (MEMO) database [4]. This
population-based, record-linkage database contains
several data sets including all dispensed community pre-
scriptions, hospital discharge data, biochemistry results,
andotherdata,allofwhicharelinkedbyanuniquepatient
identiﬁer, the community health index (CHI). Data were
anonymized,and methods approved by the Tayside Caldi-
cott Guardians. The Tayside Committee on Research
Medical Ethics also approved the study.
Study sample
Total cholesterol measurements All serum total choles-
terol measurements between 1993 and 2002 were
included in the study.Throughout the entire study period
thesemeasurementsweresubjecttorigorousinternaland
external quality control procedures. Each measurement
was categorized as treated or untreated according to
whether patients were exposed to lipid-lowering treat-
ment at the time of measurement (Table 1).
Lipid lowering treatment data Data on lipid-lowering pre-
scriptions in Tayside were available throughout the study
period. Each dispensed lipid-lowering prescription had
details of date of prescription, daily dose, amount and
duration. We were thus able to identify whether patients
were exposed to lipid-lowering treatment at the time the
total cholesterol concentration was measured.
Intention-to-treat patients Intention-to-treat patients
were those who had at least two cholesterol measure-
ments and who were prescribed lipid-lowering drug treat-
ment at some point after the ﬁrst measurement.
‘Never treated’ patients ‘Never treated’ patients were
deﬁned as patients who had two or more cholesterol mea-
surements in different calendar months,had an initial cho-
lesterol concentration of greater than 5 mmol l
-1 and were
not treated with a lipid-lowering drug at any point during
the study period.
Statistical analysis All statistical analyses were carried
out using SAS (version 8).Data were summarized as mean
(SD) for continuous variables and number of subjects (%)
for categorical variables. c
2 and t-tests and general
linear model were performed to determine signiﬁcant
differences.
Results
Between 1993 and 2002, 401 489 cholesterol measure-
ments were made on 128 240 patients. Of these, 15 064
weremadein1993and70 105in2002.Statinprescriptions
increased from 5929 in 1993 to 118 488 in 2002, at which
point they accounted for 98% of prescriptions for lipid-
lowering drugs (P < 0.01) (Table 2).The proportion of total
cholesterol measurements greater than 5 mmol l
-1 was
higher in women than in men (P < 0.01). Figure 1 shows
trends in mean total cholesterol concentration between
1993 and 2002. Cholesterol fell by 0.86 mmol l
-1 (13.9%)
(P < 0.01) in the untreated group (6.18 mmol l
-1 in 1993
(n = 1053) to 5.32 mmol l
-1 in 2002 (n = 3533)), and by
1.45 mmol l
-1 (23.5%) (P < 0.01) in the treated group
(6.17 mmol l
-1 in 1993 (n = 49) to 4.72 mmol l
-1 in 2002
(n = 1422)). More aggressive treatment during the study
period was shown by a rise in the percentage of patients
on lipid-lowering drugs attaining a target cholesterol of
Table 1
Deﬁnition of measurements and patients
Deﬁnition Total numbers
Treated measurements Patients were exposed to lipid-lowering treatment at the time the total cholesterol concentration was measured. 85 147
Untreated measurements Patients were not exposed to lipid-lowering treatment at the time the total cholesterol concentration was measured. 316 342
Intention to treat patients Patients who had at least two cholesterol measurements and were prescribed lipid-lowering drug treatment at some
point after the ﬁrst measurement.
20 179
Never treated patients Patients had two or more cholesterol measurements in different calendar months, had an initial cholesterol
concentration of greater than 5 mmol l-1 and were never treated with a lipid-lowering drug during the study period.
33 679
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-1 (62.9% in 2002 compared with 34.6%
in 1993),and by increased upward titration of statin doses
over the same period (for example 24.7% people on simv-
astatin were on 20 mg or above in 2002 compared with
12.2% in 1993 (Table 2).
Intention-to-treat cohort and never treated
cohort
Inordermorefullytoestimatetheimpactoflipid-lowering
treatment, we examined baseline and follow-up choles-
terol concentrations in those untreated patients who
were subsequently prescribed lipid-lowering treatment
(intention-to-treat patients) (Table 1 and Figure 2). The
mean follow up time was 4.6 years and the number of
measurements and the mean value of total cholesterol in
December of each year are shown in Table 3. Figure 3
shows that treated subjects (judged to be taking medica-
tion) had lower cholesterol than those untreated (judged
not to be taking treatment). Finally, we observed a fall in
cholesterol in a cohort of‘never treated’patients (Table 1).
In this group cholesterol fell by 0.38 mmol l
-1 (6.3%)
(6.06 mmol l
-1 minus 5.68 mmol l
-1) between 1993 and
2002. Table 4 shows the total cholesterol changes (last
measurement minus baseline measurement) for each
patient during follow up. Greater reductions were seen in
patients who were on lipid-lowering treatment at the time
of the last measurement than in patients who were not on
lipid-lowering treatment (P < 0.01). The mean concentra-
tion of total cholesterol changes between years 1 and 9
was 1.73 mmol l
-1 to 1.83 mmol l
-1 for patients who were
on lipid-lowering treatment and 1.18 mmol l
-1 to
1.38 mmol l
-1 for patients who were not on lipid-lowering
treatment.
Discussion
Thisstudyisimportantforseveralreasons.First,itistheﬁrst
to assess the effectiveness of lipid-lowering treatment on
cholesterol concentrations in the general population since
the publication of the ﬁrst major statin trial in 1994.
Second,becauseourdataarepopulation-based,theresult-
ant impact on cardiovascular events can be estimated.
Third,wehaveseparatelyassessedtheactualandpotential
impact of lipid-lowering treatment by examining whether
or not patients were actually taking their drugs at the time
of cholesterol measurement.
In patients who underwent cholesterol measurement
inTayside between 1993 and 2002,mean total cholesterol
concentration fell steadily throughout the study period,
and a widening gap emerged between treated and
untreatedgroups.Variousfactorsmayhaveinﬂuencedpre-
scribers and their ability to treat patients successfully to
target, including the accumulating statin evidence base
[5–9], the publication of evidence-based guidelines on
management of cholesterol [10–12], and the advent of
more potent statins during the period of study (atorvasta-
tin was launched in the United Kingdom in 1997).Choles-
terol also fell in the untreated group, in part because this
cohortwascontinuouslydepletedastreatmentthresholds
fell, with subjects switching to the treated cohort who
would previously have remained untreated.However,cho-
lesterol also fell by 6.3% in a cohort of ‘never treated’
patients, suggesting that other factors, such as increased
awareness of coronary heart disease prevention, with
resultant changes in lifestyle, and cholesterol measure-
ment in lower risk groups,may have contributed.
Cholesterol might reasonably be expected to be lower
in treated patients compared with untreated,and this was
clearly evident by the end of the study period,with choles-
terol 0.6 mmol l
-1 (5.32 mmol l
-1 minus 4.72 mmol l
-1)
lower in treated patients in 2002. However, this substan-
tially under-estimates the impact of lipid-lowering treat-
ment.Throughouttheentireperiodofthestudy,untreated
patientswhoweresubsequentlyprescribedlipid-lowering
Table 2
Treated cholesterol measurements and doses of lipid-lowering drugs by
year in Tayside population
1993
n = 1045
1998
n = 8590
2002
n = 17 897
Total cholesterol concentration (mean, SD)
Total 6.16 (1.49) 5.24 (1.11) 4.79 (1.02)
Men 5.95 (1.45) 5.31 (1.16) 4.63 (1.02)
Women 6.44 (1.48) 5.68 (1.14) 4.99 (0.99)
Total cholesterol < 5 mmol l-1 (number, %)
Total 196 (18.76) 2976 (34.64) 11 258 (62.90)
Men 138 (24.04) 1889 (41.30) 6 625 (69.19)
Women 58 (12.31) 1087 (27.07) 4 633 (55.67)
Statin doses (number, %)
Simvastatin
10 mg 475 (45.45) 2733 (31.82) 4 526 (25.29)
20 mg 127 (12.15) 1281 (14.91) 4 429 (24.74)
40 mg 0 231 (2.69) 1 282 (7.16)
80 mg 0 6 (0.07) 110 (0.61)
Pravastatin
10 mg 70 (6.70) 294 (3.42) 381 (2.13)
20 mg 55 (5.26) 194 (2.26) 674 (3.80)
40 mg 0 65 (0.76) 661 (3.77)
Atorvastatin
10 mg 0 1160 (13.50) 2 107 (11.77)
20 mg 0 629 (7.32) 1 589 (8.88)
40 mg 0 274 (3.19) 985 (5.50)
Fluvastatin
20 mg 0 442 (5.15) 317 (1.77)
40 mg 0 320 (3.72) 538 (3.01)
Cerivastatin
100 mg 0 196 (2.28) 0
200 mg 0 86 (1.00) 0
300 mg 0 29 (0.34) 0
400 mg 0 5 (0.06) 0
Total statin prescriptions
(number, %)
727 (69.57) 7945 (92.49) 17 599 (98.33)
Other lipid-lowering drug
prescriptions (number, %)
318 (30.43) 645 (7.51) 298 (1.67)
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tion than the untreated group in general (for example
6.36 mmol l
-1 compared with 5.32 mmol l
-1 in 2002).Com-
parisonofbaselineandfollow-uptotalcholesterolconcen-
trations in treated patients shows a difference in mean
total cholesterol of 1.53 mmol l
-1 in 2002 (6.36 mmol l
-1
minus 4.83 mmol l
-1).Moreover,even this conceals the full
potentialimpactoflipid-loweringtreatment.Weseparated
intention-to-treat patients into those who were or were
not actually exposed to lipid-lowering treatment at the
time of cholesterol measurement, and found, as expected
that those who were actually taking treatment achieved
lowercholesterolconcentrationsthanthosewhowerenot
(4.71 mmol l
-1 compared with 5.20 mmol l
-1 in 2002). This
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Figure 1
AllcholesterolmeasurementsinTaysidepopulation,1993–2002,categorizedbyexposuretolipid-loweringtherapyattimeofmeasurement(populationnot
exposed to lipid-lowering therapy,( );population exposed to lipid-lowering therapy,( ))
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Figure 2
Baseline ( ) and follow-up ( ) cholesterol concentration in subjects ever treated with lipid-lowering therapy (intention-to-treat patients),1993–2002
Table 3
Baseline and follow up total cholesterol concentrations at December of each calendar year in the intention-to-treat patients
Baseline total cholesterol
concentration (mmol l-1) Number of measurements
Follow-up total cholesterol
concentration (mmol l-1) Number of measurements
1993 6.82 130 6.50 50
1994 7.08 270 6.60 128
1995 6.28 309 5.61 187
1996 6.30 316 5.72 288
1997 6.41 637 5.59 620
1998 6.26 753 5.46 1242
1999 6.18 653 5.31 1219
2000 6.24 435 5.06 1482
2001 6.13 285 5.02 1456
2002 6.36 37 4.83 1830
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which have been examined in a separate study [13]. We
understand that a dispensed community prescription
does not mean that the patient is taking his treatment.
However, this is the most accurate and widely used
measure in observational studies. Thus in patients who
were actually taking lipid-lowering treatment in 2002,
mean total cholesterol was 1.65 mmol l
-1 lower than in
untreated patients (6.36 mmol l
-1 minus 4.71 mmol l
-1).
Evenifaccountistakenofotherfactorsnotdirectlyrelated
to lipid-lowering treatment which may have helped to
reduce cholesterol, the remaining difference of
1.27 mmol l
-1 (1.65 mmol l
-1 minus 0.38 mmol l
-1) is similar
to the reduction in total cholesterol seen after 3 years in
the Heart Protection Study (1.2 mmol l
-1) [9].
Data from the Cholesterol Treatment Trialists’ Collabo-
rators allow us to estimate the relative risk reduction
achieved in the Tayside population based on our ﬁndings.
In that prospective meta-analysis, a 21% reduction in
major vascular events was observed for every 1 mmol l
-1
reduction in low density lipoprotein (LDL) cholesterol [1].
In the absence of triglyceride measurements we were
unable always to calculate the LDL concentration for this
study;thisisoneofthestudylimitations.However,wehave
previously shown in the same population [14] that total
cholesterol and LDL are highly correlated. Also the Heart
Protection Study [10] showed that there were similar per-
centagereductionswithsimvastatinbetweentotalcholes-
terol and LDL. Although our data are based on total
cholesterol measurements, statins act predominantly to
reduce LDL cholesterol and accounted for nearly all pre-
scriptionsforlipid-loweringdrugsin2002.However,statins
also raise high density lipoprotein (HDL) cholesterol, and
for this reason, our ﬁndings almost certainly under-
estimate the relative risk reduction achieved.Based on our
data, the 1.53 mmol l
-1 reduction in total cholesterol seen
in the intention-to-treat patients might translate into a
32% reduction in major vascular events. In those patients
actually taking their lipid-lowering medication, the esti-
mated risk reduction is even greater (35%), based on a
1.65 mmol l
-1reductionintotalcholesterol.Ifpatientswith
a 10-year risk of developing coronary heart disease (CHD)
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Figure 3
Baseline ( ) and follow-up cholesterol concentration in subjects ever treated with lipid-lowering therapy (intention-to-treat patients),1993–2002,split by
exposure status at the time of cholesterol measurement (follow up measurement not on lipid-lowering therapy, ( ); follow up measurement on lipid-
lowering therapy,( ))
Table 4
Total cholesterol changes during the follow up period in intention-to-treat patients
Follow up time
(year)
Last measurement were not on treatment Last measurement were on treatment
Number of patients
Mean change of total
cholesterol concentration
(mmol l-1) (SD) Number of patients
Mean change of total
cholesterol concentration
(mmol l-1) (SD)
1 1643 -1.73 (1.22) 347 -1.18 (1.46)
2 1671 -1.84 (1.22) 522 -1.28 (1.54)
3 2051 -1.82 (1.30) 719 -1.30 (1.44)
4 2232 -1.72 (1.24) 772 -1.27 (1.57)
5 1857 -1.70 (1.37) 675 -1.18 (1.56)
6 1085 -1.80 (1.40) 404 -1.28 (1.33)
7 1011 -1.96 (1.38) 355 -1.40 (1.71)
8 1036 -2.06 (1.42) 340 -1.61 (1.71)
9 1648 -1.82 (1.38) 640 -1.38 (1.63)
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(the minimum recommendation of the ﬁrst Joint British
Guidelines) [11], then the relative risk reductions we have
estimated would translate into 10.5% fewer CHD events
over 10 years in those taking their lipid-lowering
medication.
In conclusion, the impact of lipid-lowering drugs
(statins) on cholesterol concentrations in the setting of
normal care is comparable with the cholesterol reductions
seen in the major statin trials. In particular, in those sub-
jects judged to be taking their medication, the beneﬁts
achievedaresubstantial.However,aroleforotherfactorsis
indicated by the fall in cholesterol seen even in the
absence of lipid-lowering treatment.
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